Oncolytics Biotech Inc. (ONCY) Q2 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Good afternoon, and welcome to OnClinic's Biotech's first quarter conference call. All participants are now in listen-only mode. There will be a question and answer session at the end of this call. Please be advised that this call is being recorded at the company's request. I would now like to turn the call over to Jan Patton, Director of Investor Relations and Communication. Please go ahead. Thank you, Operator. Today, we'll provide an update on the quarter and a review of our financials. As a reminder, various remarks made during this call contain certain forward-looking statements relating to the company's business prospects and the development and commercialization of Pella Rear Rep, including statements regarding the company's ongoing CEO search, our mission, strategies, and milestones, the company's belief as to the potential and mechanism of action of Pella Rear Rep as a cancer therapeutic, our potential registrational opportunities for Pella Rear Rep, and our plans and strategies related thereto, our plans to continue enrollment in Goblet Cohort 5, our ongoing business development initiatives, and other statements related to anticipated developments in the company's business. These statements are based on management's current expectations and beliefs and are subject to a number of factors which involve none and no known risk delays, uncertainties, and other factors not under the company's control that may cause actual results, performance, or achievements of the company to be materially different from the results, performance, or expectations implied by these forward-looking statements. In any forward-looking statement in which Oncologics expresses an expectation or belief as to future results, Such expectations or beliefs are expressed in good faith, and our...